HOUSE BILL

55TH LEGISLATURE - STATE OF NEW MEXICO - SECOND SESSION, 2022

INTRODUCED BY

DISCUSSION DRAFT

FOR THE LEGISLATIVE HEALTH AND HUMAN SERVICES COMMITTEE

AN ACT

RELATING TO HEALTH INSURANCE COVERAGE; ENACTING SECTIONS OF THE HEALTH CARE PURCHASING ACT, THE PUBLIC ASSISTANCE ACT, THE NEW MEXICO INSURANCE CODE, THE HEALTH MAINTENANCE ORGANIZATION LAW AND THE NONPROFIT HEALTH CARE PLAN LAW TO REQUIRE COVERAGE OF BIOMARKER TESTING.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF NEW MEXICO:

SECTION 1. A new section of the Health Care Purchasing Act is enacted to read:

"[NEW MATERIAL] BIOMARKER TESTING INSURER COVERAGE.--

A. Group health coverage, including self-insurance, offered, issued, amended, delivered or renewed under the Health Care Purchasing Act shall provide coverage for insureds to receive biomarker testing.

B. Coverage provided pursuant to this section

underscored material = new
[bracketed material] = delete

shall be for the purposes of diagnosis, treatment, appropriate management or ongoing monitoring of an insured's disease or condition when the test is supported by medical and scientific evidence, including:

(1) labeled indications for a United States food and drug administration-approved or -cleared test or indicated tests for a United States food and drug administration-approved drug;

(2) federal centers for medicare and medicaid services national coverage determinations and medicare administrative contractor local coverage determinations; or

(3) nationally recognized clinical practice guidelines and consensus statements.

C. An insurer providing coverage for biomarker testing pursuant to this section shall ensure that:

(1) coverage is provided in a manner that limits disruptions in care, including coverage for multiple biopsies or biospecimen samples; and

(2) a patient and a practitioner who prescribes biomarker testing have clear, accessible and convenient processes to request an exception to a coverage policy of a health insurer and that those processes are accessible on the insurer's website.

D. Coverage for biomarker testing may be subject to deductibles and coinsurance consistent with those imposed on

underscored material = new
[~~bracketed material~~] = delete

other benefits under the same group health care coverage, including any form of self-insurance.

E. As used in this section:

(1) "biomarker" means a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacologic responses to a specific therapeutic intervention and includes gene mutations or protein expressions;

(2) "biomarker testing" means analysis of a patient's tissue, blood or other biospecimen for the presence of a biomarker and includes single-analyte tests, multi-plex panel tests and whole genome sequencing;

(3) "consensus statements" means statements that are:

(a) developed by an independent, multidisciplinary panel of experts using a transparent methodology and reporting structure and with a conflict-of-interest policy; and

(b) aimed at specific clinical circumstances and based on the best available evidence for the purpose of optimizing the outcomes of clinical care; and

(4) "nationally recognized clinical practice guidelines" means evidence-based clinical practice guidelines that are:

(a) developed by independent

underscored material = new
[~~bracketed material~~] = delete

organizations or medical professional societies using a transparent methodology and reporting structure and with a conflict-of-interest policy; and

(b) used to establish standards of care informed by a systematic review of evidence and an assessment of the benefits and costs of alternative care options and include recommendations intended to optimize patient care."

SECTION 2. A new section of the Public Assistance Act is enacted to read:

"[NEW MATERIAL] BIOMARKER TESTING COVERAGE.--

A. In accordance with federal law, the secretary shall adopt and promulgate rules that provide medical assistance coverage for enrollees to receive biomarker testing.

B. A medical assistance plan providing coverage pursuant to this section shall be for the purposes of diagnosis, treatment, appropriate management or ongoing monitoring of an enrollee's disease or condition when the test is supported by medical and scientific evidence, including:

(1) labeled indications for a United States food and drug administration-approved or -cleared test or indicated tests for a United States food and drug administration-approved drug;

(2) federal centers for medicare and medicaid services national coverage determinations and medicare administrative contractor local coverage determinations; or

underscored material = new
[bracketed material] = delete

(3) nationally recognized clinical practice guidelines and consensus statements.

C. Medicaid contractors delivering services to enrollees shall provide biomarker testing at the same scope, duration and frequency as the medical assistance plan otherwise provides to enrollees.

D. A medical assistance plan providing coverage for biomarker testing pursuant to this section shall ensure that:

(1) coverage is provided in a manner that limits disruptions in care, including coverage for multiple biopsies or biospecimen samples; and

(2) a patient and a practitioner who prescribes biomarker testing have clear, readily accessible and convenient processes to request an exception to a coverage policy of a health insurer and that those processes are accessible on the medical assistance division of the department's website.

E. As used in this section:

(1) "biomarker" means a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacologic responses to a specific therapeutic intervention, including gene mutations or protein expressions;

(2) "biomarker testing" means analysis of a patient's tissue, blood or other biospecimen for the presence

underscored material = new
[bracketed material] = delete

of a biomarker and includes single-analyte tests, multi-plex panel tests and whole genome sequencing;

(3) "consensus statements" means statements that are:

(a) developed by an independent, multidisciplinary panel of experts using a transparent methodology and reporting structure and with a conflict-of-interest policy; and

(b) aimed at specific clinical circumstances and based on the best available evidence for the purpose of optimizing the outcomes of clinical care; and

(4) "nationally recognized clinical practice guidelines" means evidence-based clinical practice guidelines that are:

(a) developed by independent organizations or medical professional societies using a transparent methodology and reporting structure and with a conflict-of-interest policy; and

(b) used to establish standards of care informed by a systematic review of evidence and an assessment of the benefits and costs of alternative care options and include recommendations intended to optimize patient care."

SECTION 3. A new section of Chapter 59A, Article 23 NMSA 1978 is enacted to read:

"[NEW MATERIAL] BIOMARKER TESTING COVERAGE.--

underscored material = new
[~~bracketed material~~] = delete

A. A blanket or group health insurance policy, health care plan or certificate of health insurance that is delivered, issued for delivery or renewed in this state shall provide coverage for insureds to receive biomarker testing.

B. Coverage provided pursuant to this section shall be for the purposes of diagnosis, treatment, appropriate management or ongoing monitoring of an insured's disease or condition when the test is supported by medical and scientific evidence, including:

(1) labeled indications for a United States food and drug administration-approved or -cleared test or indicated tests for a United States food and drug administration-approved drug;

(2) federal centers for medicare and medicaid services national coverage determinations and medicare administrative contractor local coverage determinations; or

(3) nationally recognized clinical practice guidelines and consensus statements.

C. A blanket or group health policy, health care plan or certificate of health insurance providing coverage for biomarker testing pursuant to this section shall ensure that:

(1) coverage is provided in a manner that limits disruptions in care, including coverage for multiple biopsies or biospecimen samples; and

(2) a patient and a practitioner who

underscored material = new
[~~bracketed material~~] = delete

prescribes biomarker testing have clear, accessible and convenient processes to request an exception to a coverage policy of a health insurer and that those processes are accessible on the insurer's website.

D. Coverage for biomarker testing may be subject to deductibles and coinsurance consistent with those imposed on other benefits under the same policy, plan or certificate.

E. As used in this section:

(1) "biomarker" means a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacologic responses to a specific therapeutic intervention and includes gene mutations or protein expressions;

(2) "biomarker testing" means analysis of a patient's tissue, blood or other biospecimen for the presence of a biomarker and includes single-analyte tests, multi-plex panel tests and whole genome sequencing;

(3) "consensus statements" means statements that are:

(a) developed by an independent, multidisciplinary panel of experts using a transparent methodology and reporting structure and with a conflict-of-interest policy; and

(b) aimed at specific clinical circumstances and based on the best available evidence for the

underscored material = new
[bracketed material] = delete

purpose of optimizing the outcomes of clinical care; and

(4) "nationally recognized clinical practice guidelines" means evidence-based clinical practice guidelines that are:

(a) developed by independent organizations or medical professional societies using a transparent methodology and reporting structure and with a conflict-of-interest policy; and

(b) used to establish standards of care informed by a systematic review of evidence and an assessment of the benefits and costs of alternative care options and include recommendations intended to optimize patient care."

SECTION 4. A new section of the Health Maintenance Organization Law is enacted to read:

"[NEW MATERIAL] BIOMARKER TESTING COVERAGE.--

A. An individual or group health maintenance organization contract that is delivered, issued for delivery or renewed in this state shall provide coverage for eligible enrollees to receive biomarker testing.

B. Coverage provided pursuant to this section shall be for the purposes of diagnosis, treatment, appropriate management or ongoing monitoring of an enrollee's disease or condition when the test is supported by medical and scientific evidence, including:

(1) labeled indications for a United States

underscored material = new
[bracketed material] = delete

food and drug administration-approved or -cleared test or indicated tests for a United States food and drug administration-approved drug;

(2) federal centers for medicare and medicaid services national coverage determinations and medicare administrative contractor local coverage determinations; or

(3) nationally recognized clinical practice guidelines and consensus statements.

C. A health maintenance organization contract providing coverage for biomarker testing pursuant to this section shall ensure that:

(1) coverage is provided in a manner that limits disruptions in care, including coverage for multiple biopsies or biospecimen samples; and

(2) a patient and a practitioner who prescribes biomarker testing have clear, accessible and convenient processes to request an exception to a coverage policy of a carrier and that those processes are accessible on the carrier's website.

D. Coverage for biomarker testing may be subject to deductibles and coinsurance consistent with those imposed on other benefits under the same contract.

E. As used in this section:

(1) "biomarker" means a characteristic that is objectively measured and evaluated as an indicator of normal

underscored material = new
[~~bracketed material~~] = delete

biological processes, pathogenic processes or pharmacologic responses to a specific therapeutic intervention and includes gene mutations or protein expression;

(2) "biomarker testing" means analysis of a patient's tissue, blood or other biospecimen for the presence of a biomarker and includes single-analyte tests, multi-plex panel tests and whole genome sequencing;

(3) "consensus statements" means statements that are:

(a) developed by an independent, multidisciplinary panel of experts using a transparent methodology and reporting structure and with a conflict-of-interest policy; and

(b) aimed at specific clinical circumstances and based on the best available evidence for the purpose of optimizing the outcomes of clinical care; and

(4) "nationally recognized clinical practice guidelines" means evidence-based clinical practice guidelines that are:

(a) developed by independent organizations or medical professional societies using a transparent methodology and reporting structure and with a conflict-of-interest policy; and

(b) used to establish standards of care informed by a systematic review of evidence and an assessment

underscored material = new
[bracketed material] = delete

of the benefits and costs of alternative care options and include recommendations intended to optimize patient care."

SECTION 5. A new section of the Nonprofit Health Care Plan Law is enacted to read:

"[NEW MATERIAL] BIOMARKER TESTING COVERAGE.--

A. An individual or group health care plan that is delivered, issued for delivery or renewed in this state shall provide coverage for subscribers to receive biomarker testing.

B. Coverage provided pursuant to this section shall be for the purposes of diagnosis, treatment, appropriate management or ongoing monitoring of a subscriber's disease or condition when the test is supported by medical and scientific evidence, including:

(1) labeled indications for a United States food and drug administration-approved or -cleared test or indicated tests for a United States food and drug administration-approved drug;

(2) federal centers for medicare and medicaid services national coverage determinations and medicare administrative contractor local coverage determinations; or

(3) nationally recognized clinical practice guidelines and consensus statements.

C. Health care plans providing coverage for biomarker testing pursuant to this section shall ensure that:

(1) coverage is provided in a manner that

underscored material = new
[bracketed material] = delete

limits disruptions in care, including coverage for multiple biopsies or biospecimen samples; and

(2) a patient and a practitioner who prescribes biomarker testing have clear, accessible and convenient processes to request an exception to a coverage policy of a health care plan and that those processes are accessible on the health care plan's website.

D. Coverage for biomarker testing may be subject to deductibles and coinsurance consistent with those imposed on other benefits under the same policy, plan or certificate.

E. As used in this section:

(1) "biomarker" means a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacologic responses to a specific therapeutic intervention and includes gene mutations or protein expressions;

(2) "biomarker testing" means analysis of a patient's tissue, blood or other biospecimen for the presence of a biomarker and includes single-analyte tests, multi-plex panel tests and whole genome sequencing;

(3) "consensus statements" means statements that are:

(a) developed by an independent, multidisciplinary panel of experts using a transparent methodology and reporting structure and with a conflict-of-

underscored material = new
[bracketed material] = delete

interest policy; and

(b) aimed at specific clinical circumstances and based on the best available evidence for the purpose of optimizing the outcomes of clinical care; and

(4) "nationally recognized clinical practice guidelines" means evidence-based clinical practice guidelines that are:

(a) developed by independent organizations or medical professional societies using a transparent methodology and reporting structure and with a conflict-of-interest policy; and

(b) used to establish standards of care informed by a systematic review of evidence and an assessment of the benefits and costs of alternative care options and include recommendations intended to optimize patient care."

SECTION 6. APPLICABILITY.--The provisions of this act apply to health insurance policies, health care plans, certificates of health insurance or health maintenance organization contracts that are delivered, issued for delivery or renewed in this state on or after January 1, 2023.

underscored material = new
[~~bracketed material~~] = delete